Vanda Pharma looks an interesting situation.The company's got the drug and looks to be getting the marketing under way.The market is apparently not that big but pretty much their own.It seems the drug should be profitable with mktg and BMY royalties the main expenses. I'd guess the mktg should decline over time as well.Patent goes through 2017, with likely extension, they say, to 2022.Ok, where's the booby trap and what's the downside?
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings